BACKGROUND: Overexpression of epidermal growth factor receptor (EGFR) is related to poor prognosis in patients with head and neck cancer (HNC) treated with surgery or radiotherapy. We assessed the relationship between EGFR status and outcome in patients treated with concurrent chemoradiotherapy. PATIENTS AND METHODS: Among 149 patients with unresectable HNC treated with chemoradiotherapy, immunohistochemistry was performed on 122 available tumor specimens. The following factors were included in the analysis: age at diagnosis, gender, performance status, site of primary tumor, T- and N-stage, grading, pretreatment, treatment protocol and EGFR staining. RESULTS: Overall, 43/122 (35%) were considered positive. At a median follow-up of 45 months, 5-year survival did not differ between positive and negative cases (42.1% vs. 48.0% respectively: hazard ratio for death 1.23; 95% confidence interval 0.70 to 2.17, p=0.45) nor was 5-year progression-free survival and 5-year locoregional control. Only when a smaller subgroup of tumors showing the strongest EGFR expression was considered, was any difference in 5-year overall survival detected (33.6% vs. 50.1%, p=0.009). CONCLUSION: EGFR appears to have no prognostic value when chemoradiotherapy is used. Possibly a small subgroup of cases with stronger positivity and worse prognosis can be identified.
BACKGROUND: Overexpression of epidermal growth factor receptor (EGFR) is related to poor prognosis in patients with head and neck cancer (HNC) treated with surgery or radiotherapy. We assessed the relationship between EGFR status and outcome in patients treated with concurrent chemoradiotherapy. PATIENTS AND METHODS: Among 149 patients with unresectable HNC treated with chemoradiotherapy, immunohistochemistry was performed on 122 available tumor specimens. The following factors were included in the analysis: age at diagnosis, gender, performance status, site of primary tumor, T- and N-stage, grading, pretreatment, treatment protocol and EGFR staining. RESULTS: Overall, 43/122 (35%) were considered positive. At a median follow-up of 45 months, 5-year survival did not differ between positive and negative cases (42.1% vs. 48.0% respectively: hazard ratio for death 1.23; 95% confidence interval 0.70 to 2.17, p=0.45) nor was 5-year progression-free survival and 5-year locoregional control. Only when a smaller subgroup of tumors showing the strongest EGFR expression was considered, was any difference in 5-year overall survival detected (33.6% vs. 50.1%, p=0.009). CONCLUSION:EGFR appears to have no prognostic value when chemoradiotherapy is used. Possibly a small subgroup of cases with stronger positivity and worse prognosis can be identified.
Authors: Larissa Sweeny; Nichole R Dean; J Scott Magnuson; William R Carroll; Emily E Helman; Stephen O Hyde; Renee L Desmond; Eben L Rosenthal Journal: Head Neck Date: 2011-07-07 Impact factor: 3.147
Authors: Julie E Bauman; Umamaheswar Duvvuri; William E Gooding; Tanya J Rath; Neil D Gross; John Song; Antonio Jimeno; Wendell G Yarbrough; Faye M Johnson; Lin Wang; Simion Chiosea; Malabika Sen; Jason Kass; Jonas T Johnson; Robert L Ferris; Seungwon Kim; Fred R Hirsch; Kimberly Ellison; John T Flaherty; Gordon B Mills; Jennifer R Grandis Journal: JCI Insight Date: 2017-03-23
Authors: Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram Journal: Laryngoscope Date: 2016-08-31 Impact factor: 3.325
Authors: Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha Journal: Head Neck Date: 2012-08-21 Impact factor: 3.147
Authors: Silke Wemmert; Yasmin Lindner; Johannes Linxweiler; Stefan Wagenpfeil; Rainer Bohle; Marcus Niewald; Bernhard Schick Journal: Oncol Lett Date: 2016-01-20 Impact factor: 2.967